NCT05118841View on ClinicalTrials.gov

Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 3, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

May 31, 2024

Conditions
Advanced Solid Tumor
Interventions
DRUG

ZX-4081

Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle

Trial Locations (1)

28078

RECRUITING

Carolina BioOncology, Huntersville

Sponsors
All Listed Sponsors
lead

Nanjing Zenshine Pharmaceuticals

INDUSTRY

NCT05118841 - Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter